Is Rite Aid the Best Pharmacy Stock?

This third-place company is out in front of the aging baby boomer movement, making it one of the best growth opportunities in the healthcare space.

Jul 22, 2014 at 2:00PM

Health wellness is no longer just a fad. First, there's the rising consumption of vitamins and supplements. Second, there's the rising demand for drugs. Both of these are being driven by a rapidly aging population in the U.S. But it's not the likes of Walgreen (NASDAQ:WBA) or CVS (NYSE:CVS) that will be the biggest benefactors. Rather, it's the No. 3 player in the industry, Rite Aid (NYSE:RAD).

Rite Aid has over 4,500 stores and is the third largest pharmacy in the U.S. based on store count and revenues. It not only operates pharmacies but also offers clinical services. It extended its presence in the clinic industry earlier this year with its acquisition of RediClinic.

Capitalizing on vitamins
One of Rite Aid's biggest opportunities includes a partnership with GNC. Just this year, it extended its partnership through 2019. This is a key positive, as it's a long-term play on the rise of the health-conscious consumer. Rite Aid plans to add 300 GNC LiveWell store-in-a-stores over the next five years, in addition to the 2,200 already in Rite Aids.

Rite Aid is also remodelling many stores to the Wellness format (which includes a big store redesign and more focus on clinical services). It also has a customer loyalty program via Wellness+.

Boosting margins and long-term growth
One of the best opportunities in pharma is to capitalize on aging baby boomers. This includes not only increasing exposure to vitamins and supplements, but also generics. Both of which Rite Aid is doing.

Generic drugs are generally less expensive and have higher gross margins for pharmacies. There are also a number of key medicines that will lose their patents in 2015, driving a lot more generic medications onto the market. Earlier this year, Rite Aid extended its agreement (for five years) with its key generic drug distributor, McKesson.

Rite Aid isn't the only company looking to tap the generics market -- so are Walgreen and CVS. The three key drug distributors (distributing 80% of all drugs in the U.S. collectively) are McKesson, Cardinal, and AmerisourceBergen. Rite Aid has a new deal with McKesson, and Cardinal recently signed a 10-year deal with CVS. Meanwhile, AmerisourceBergen signed a 10-year deal with Walgreen and Alliance Boots.

CVS is less of a play on retail pharmacies, where about 50% of its revenues are derived from its pharmacy benefits management segment. However, Walgreen became a larger player in the global pharmacy market earlier this year. Its 45% ownership of Alliance Boots (and potential purchase of the remaining part of the company) gives Walgreen leverage in the generic drug market, allowing it to purchase drugs cheaper, given it's now the world's largest purchaser of generic drugs.

How shares stack up
Shares of Rite Aid trade at a P/E of 15 based on next year's earnings estimates. Walgreen trades at 18, but CVS only trades at 15.4. However, one of the most compelling metrics for Rite Aid is its P/E to growth rate (PEG) ratio, which is right at 1.0. Compare that to to CVS's 1.4 and Walgreen's 1.6. What's more is that Rite Aid has the best return on investment, coming in at 18%, while CVS and Walgreen's are right at 10%. 

Bottom line
Although it's rather underrated, Rite Aid appears to be the cheapest option in the major pharma retail industry, but it also has a number of growth opportunities. For investors looking for a solid play on the rising demand for drugs and vitamins, Rite Aid is worth a closer look.

Leaked: This coming blockbuster will make even Rite Aid jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Marshall Hargrave has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers